A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer Meeting Abstract
| Authors: | Chung, C.; Colevas, D.; Adkins, D.; Park, J. C.; Rodriguez, C.; Gibson, M.; Sukari, A.; Burtness, B.; Johnson, F.; Julian, R.; Saba, N.; Dunn, L.; Seiwert, T.; Worden, F.; Haddad, R.; Gabrail, N.; Bauman, J.; Agensky, L.; Goel, A.; Lynam, R.; Margossian, S.; Moniz, R.; Quayle, S.; Rajan, C.; Pienta, K.; Levisetti, M.; Pai, S. |
| Abstract Title: | A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer |
| Meeting Title: | 37th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2022) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 10 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Nov 8-12 |
| Meeting Location: | Boston, MA |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2022-11-01 |
| Start Page: | A711 |
| Language: | English |
| ACCESSION: | WOS:000919423400640 |
| DOI: | 10.1136/jitc-2022-SITC2022.0681 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 681 -- Source: Wos |
